Valter Gattei Selected Research

Proteins (Proteins, Gene)

10/2022	Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.
1/2020	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
4/2011	Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.
1/2010	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.
1/2008	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
7/2006	ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.
12/2004	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
1/2004	CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.
3/2002	Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Valter Gattei Research Topics

Disease

62	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2024 - 09/2004
27	Neoplasms (Cancer) 03/2024 - 02/2002
12	Lymphoma (Lymphomas) 12/2023 - 10/2005
8	Disease Progression 03/2024 - 12/2004
7	Vasculitis (Vasculitides) 10/2023 - 03/2018
6	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 06/2003
6	Residual Neoplasm 01/2023 - 02/2002
5	Leukemia 01/2020 - 11/2002
4	Glomerulonephritis 01/2023 - 07/2015
4	B-Cell Lymphoma (Lymphoma, B Cell) 10/2022 - 06/2008
4	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 01/2008
3	Infections 01/2024 - 09/2004
3	Lymphocytosis 10/2023 - 01/2018
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2023 - 12/2020
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 09/2004
3	Pathologic Complete Response 01/2023 - 01/2008
3	Trisomy (Trisomies) 01/2020 - 11/2013
3	Multiple Myeloma 01/2016 - 05/2002
3	Hodgkin Disease (Hodgkin's Disease) 01/2003 - 02/2002
2	Cryoglobulinemia 10/2023 - 01/2021
2	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2014
2	Fibrosis (Cirrhosis) 11/2021 - 09/2004
2	Virus Diseases (Viral Diseases) 11/2021 - 01/2017
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2020 - 01/2019
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2018 - 12/2017
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2017 - 01/2004
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2016 - 08/2015
2	Testicular Neoplasms (Testicular Cancer) 10/2005 - 02/2005
1	Heart Failure 01/2024
1	Sudden Death 01/2024
1	Hemorrhage 01/2024
1	Lymphadenopathy 12/2023
1	Leg Ulcer 01/2023
1	Arthritis (Polyarthritis) 10/2022
1	Hepatocellular Carcinoma (Hepatoma) 03/2022
1	Chronic Hepatitis C 11/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Skin Ulcer 12/2020
1	Hypoxia (Hypoxemia) 01/2020

Drug/Important Bio-Agent (IBA)

15	ibrutinibIBA 01/2024 - 12/2014
13	Rituximab (Mabthera)FDA Link 01/2023 - 02/2002
11	Antiviral Agents (Antivirals)IBA 10/2023 - 12/2014
10	fludarabineIBA 01/2023 - 12/2005
9	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2002
8	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022 - 09/2004
7	IntegrinsIBA 01/2023 - 05/2015
7	Integrin alpha4beta1 (VLA-4)IBA 01/2023 - 05/2015
7	AntigensIBA 01/2016 - 09/2004
6	Surface Antigens (Surface Antigen)IBA 01/2016 - 07/2005
5	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2008
4	idelalisibIBA 12/2023 - 04/2021
4	LigandsIBA 12/2023 - 07/2007
4	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 12/2014
4	MicroRNAs (MicroRNA)IBA 01/2023 - 10/2014
4	Monoclonal AntibodiesIBA 05/2016 - 10/2005
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 10/2015
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2020
3	nasIBA 10/2022 - 12/2020
3	NucleotidesIBA 10/2022 - 11/2013
3	DNA (Deoxyribonucleic Acid)IBA 10/2022 - 10/2005
3	Messenger RNA (mRNA)IBA 01/2020 - 03/2002
3	CytokinesIBA 09/2004 - 02/2002
2	Lapatinib (GW572016)FDA Link 12/2023 - 01/2023
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2022 - 05/2009
2	InterferonsIBA 11/2021 - 07/2015
2	ChemokinesIBA 01/2018 - 05/2009
2	nutlin 3IBA 11/2013 - 04/2009
2	ZAP-70 Protein-Tyrosine Kinase (ZAP 70 Protein Tyrosine Kinase)IBA 08/2006 - 12/2005
2	Interleukin-3 (Interleukin 3)IBA 01/2003 - 02/2002
2	Stem Cell FactorIBA 01/2003 - 09/2002
2	Interleukin-9 (Interleukin 9)IBA 09/2002 - 02/2002
1	venetoclaxIBA 12/2023
1	RNA (Ribonucleic Acid)IBA 10/2023
1	AntibodiesIBA 01/2023
1	acalabrutinibIBA 01/2023
1	ProteomeIBA 10/2022
1	Fibronectins (Fibronectin)IBA 04/2022
1	ElastinIBA 04/2022
1	Azacitidine (5 Azacytidine)FDA Link 03/2022
1	OligonucleotidesIBA 01/2022
1	Integrin beta1IBA 01/2022
1	serum P-component (CIt)IBA 10/2021
1	2,2- bis(hydroxymethyl)- 1- azabicyclo(2,2,2,)octan- 3- oneIBA 01/2021
1	Bendamustine Hydrochloride FDA Link 01/2021
1	Hormones (Hormone)IBA 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	NucleosidesIBA 01/2021
1	Phenobarbital (Luminal)FDA Link 01/2021
1	ElementsIBA 12/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Peptide Elongation Factors (Elongation Factor)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Hypoxia-Inducible Factor 1IBA 01/2020
1	OTX015IBA 12/2018
1	ChromatinIBA 12/2018

Therapy/Procedure

33	Therapeutics 01/2024 - 12/2004
4	Drug Therapy (Chemotherapy) 03/2024 - 12/2005
3	Time-to-Treatment 01/2012 - 01/2008
2	Plasma Exchange 01/2023 - 10/2022
1	Aftercare (After-Treatment) 01/2023